DERM stock investors are getting excited and for good reason too. Dermira (NASDAQ:DERM) released positive progress for a key drug candidate, lebrikizumab, back in mid-March and shares have been climbing since.
Since March 15th, DERM stock is up a whopping 114%, after closing at $6.84 on March 14th.
The Value Behind LebrikizumabDermira experienced a huge setback in March last year when its drug candidate for acne flopped. After the results became public, investors deserted DERM stock, leaving it to tank 69% in a matter of days. Interestingly, the biopharmaceutical company had, in August ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.